Keeping pace with immuno oncology research breakthroughs and biomarker identification

The excitement surrounding immuno-oncology is being driven by results seen in the clinic. New treatments can potentially be made more efficacious using NGS technology that would accelerate biomarker identification and bring down costs for research subject screening and safety monitoring. Among these NGS technologies is RNA-Seq, a flexible sequencing assay that enables multiple applications with one assay from a single sample. This presentation will summarize the clinical relevance of RNA-Seq, when and how to use expression profiling economically, some common challenges and associated remedies.

Adrian Benjamin, Sr. Commercial Development Manager, Oncology, Illumina
Kimberly Robasky, Ph.D., Lead Scientist, Bioinformatics and Clinical Systems, Q² Solutions